The odds seem against Levo Therapeutics, Inc.’s carbetocin nasal spray getting an advisory committee endorsement for treatment of hyperphagia (unrelenting hunger) associated with Prader Willi syndrome given the US FDA’s negative assessment of the company’s data.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?